Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395350 | 0.84 | HTT (0.41) | HTTPOLBDHFRSMN1; SMN2NOS3 | |
| SCHEMBL19971997 | 0.83 | HTT (0.39) | HTTPOLBDHFRSMN1; SMN2NOS3 | |
| SCHEMBL9194864 | 0.79 | SMN1; SMN2 (0.32) | DHFRSMN1; SMN2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL19972000 | 0.76 | HTT (0.36) | HTTPOLBDHFRNOS3NOS1 | |
| SCHEMBL393744 | 0.75 | HTT (0.43) | HTTPOLBDHFRSMN1; SMN2NOS3 | |
| SCHEMBL19972051 | 0.74 | GABRA1 (0.38) | HTTPOLBDHFRSMN1; SMN2NOS3 | |
| SCHEMBL117142 | 0.74 | HTT (0.46) | HTTPOLBDHFRSMN1; SMN2NOS3 | |
| SCHEMBL6400103 | 0.73 | POLB (0.38) | HTTPOLBDHFRSMN1; SMN2NOS3 | |
| SCHEMBL9799254 | 0.73 | POLB (0.38) | HTTPOLBDHFRSMN1; SMN2NOS3 | |
| SCHEMBL15272 | 0.71 | ALDH1A1 (0.42) | HTTPOLBDHFRNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957241-B2 | Aromatic diamine, an intermediate therefor, a method for producing the aromatic diamine, and a method for producing the intermediate therefor | SEIKA CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | SEIKA CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | WEE1, WEE2, WASF2 | HTT 3592/4885POLB 2855/4885DHFR 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.